search
Back to results

Analysis of CRBSI Rates in Patients With a NexSite™ HD (Hemodialysis) Catheter

Primary Purpose

End Stage Renal Disease

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
NexSite HD Patients
Sponsored by
Marvao Medical
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for End Stage Renal Disease

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. The patient shall be 18 - 80 years old.
  2. The patient requires the placement of a long term tunnelled HD catheter for administration of hemodialysis.
  3. The patient has anticipated survival in excess of 90 days from the anticipated date of catheter placement.
  4. The patient has the ability to understand the research subject information and sign a written Informed Consent form which must be obtained prior to initiation of the study.
  5. The patient receives the catheter via the internal jugular or subclavian vein.
  6. All female patients of child bearing potential must complete a negative pregnancy test and will confirm that they are not breastfeeding.

Exclusion Criteria:

  1. The patient is participating in another IRB (Institutional Review Board) clinical trial, which modifies standard-of-care treatment and/or involves an investigational device or drug.
  2. The patient has a confirmed or suspected infection, bacteraemia or septicaemia.
  3. The patient's physiology is NOT suitable for placement of the NexSite device; this will include an examination of the anatomy at the proposed catheter exit site.
  4. The patient is known or suspected to have allergies to the materials used in the construction of the device.
  5. The patient has previously suffered from coagulation issues or has had vascular surgery at the proposed placement site.
  6. The patient has received radiation treatment at the proposed catheter placement site.
  7. The patient has severe chronic obstructive lung disease.
  8. The patient is pyretic within 72 hours (temperature ≥38o C or 100.4oF) prior to placement and/or has received antimicrobial drugs within two weeks prior to catheterisation.
  9. The patient is female of child bearing potential not using adequate contraception. (Adequate contraception is defined as abstinence, intrauterine device [IUD], birth control pills, or spermicidal gel with diaphragm or condom)
  10. The patient has another indwelling catheter.
  11. The patient has non-healing diabetic foot ulcers.
  12. The patient did not give informed consent.
  13. The patient would be unavailable for follow-up.
  14. The patient is a permanent nursing home resident.
  15. The proposed access site is not the internal jugular or subclavian vein.
  16. The patient is scheduled to undergo an elective surgical procedure (other than a procedure to create a graft or fistula) within the study timeframe.
  17. Any other condition that the Investigator believes should exclude the patient from the study.
  18. The patient does not have English or Spanish as their first language.

Sites / Locations

  • Eastern Nephrology Associates
  • Eastern Nephology Associates
  • Capital Nephrology Associates
  • South Carolina Nephrology and Hypertension Center Inc
  • Lubbock Vascular Access Centre
  • Renal Associates

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

NexSite HD Patients

Arm Description

NexSite HD patient catheter device placement

Outcomes

Primary Outcome Measures

Number of participants with Catheter-Related Blood Stream Infection (CRBSI)(bacteremia/fungemia) as an adverse event.
Number of participants with a confirmed CRBSI for the duration of catheter use or to 180 days post device placement (whichever occurs first)

Secondary Outcome Measures

Number of participants with adverse events associated with device placement and use.
Number of participants with adverse events associated with device placement and for the duration of catheter use or to 180 days post device placement.
Number of participants with unhealed catheter exit sites
Number of participants with unhealed exit sites for the duration of catheter use or to 180 days post device placement (whichever occurs first)
Number of participants with tunnel infection as an adverse event
Number of participants with a tunnel infection for the duration of catheter use or to 180 days post device placement (whichever occurs first)
Number of participants with exit site infection as an adverse event
Number of participants with a exit site infection for the duration of catheter use or to 180 days post device placement (whichever occurs first)
Number of participants with Pneumothorax, haemothorax, arrhythmia, air embolism or arterial perforation as an adverse event.
Number of participants with non-infectious catheter complications within one day of placement.
Number of participants with Catheter dislodgement, Catheter tip dislodgement and catheter thrombosis as an adverse event.
Number of participants with late non infectious complications for the duration of catheter use or to 180 days post device placement (whichever occurs first).

Full Information

First Posted
May 18, 2015
Last Updated
September 28, 2018
Sponsor
Marvao Medical
search

1. Study Identification

Unique Protocol Identification Number
NCT02453646
Brief Title
Analysis of CRBSI Rates in Patients With a NexSite™ HD (Hemodialysis) Catheter
Official Title
Analysis of CRBSI (Catheter-Related Blood Stream Infection) Rates in Patients With a NexSite™ HD (Hemodialysis) Catheter
Study Type
Interventional

2. Study Status

Record Verification Date
September 2018
Overall Recruitment Status
Completed
Study Start Date
April 2015 (Actual)
Primary Completion Date
September 2017 (Actual)
Study Completion Date
July 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Marvao Medical

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
A U.S. multi-centre post approval registry to analyse the CRBSI rate in patients with the NexSite HD Catheter for long term vascular access for hemodialysis.
Detailed Description
This is a U.S. multi - centre, prospective, non-randomized post approval registry. Approximately one hundred and twenty patients will be implanted with a NexSite HD catheter at four to eight U.S. sites where hemodialysis catheters are routinely implanted. Each site may enrol a maximum of 50 patients. Enrolled patients will be followed from device placement to device removal or 180 days post device placement. Patients will be enrolled once only. The primary endpoint is CRBSI rate related to the NexSite HD catheter. Determination of infection will be decided by the investigator and if necessary adjudicated by the CEC (Clinical Events Committee) based on blood culture results, regardless of whether the catheter is removed. Secondary endpoints for the study are Successful placement and continued use of the NexSite HD device designed for use in patients requiring long term hemodialysis. Healing of catheter exit site Tunnel Infections Exit site infections Early non-infectious complications associated with CVCs Late non-infectious complications associated with Central Venous Catheters

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
End Stage Renal Disease

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
120 (Actual)

8. Arms, Groups, and Interventions

Arm Title
NexSite HD Patients
Arm Type
Experimental
Arm Description
NexSite HD patient catheter device placement
Intervention Type
Device
Intervention Name(s)
NexSite HD Patients
Intervention Description
Measurement of CRBSI rate and other device related adverse events in patients with NexSite HD Catheter.
Primary Outcome Measure Information:
Title
Number of participants with Catheter-Related Blood Stream Infection (CRBSI)(bacteremia/fungemia) as an adverse event.
Description
Number of participants with a confirmed CRBSI for the duration of catheter use or to 180 days post device placement (whichever occurs first)
Time Frame
Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)
Secondary Outcome Measure Information:
Title
Number of participants with adverse events associated with device placement and use.
Description
Number of participants with adverse events associated with device placement and for the duration of catheter use or to 180 days post device placement.
Time Frame
Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)
Title
Number of participants with unhealed catheter exit sites
Description
Number of participants with unhealed exit sites for the duration of catheter use or to 180 days post device placement (whichever occurs first)
Time Frame
Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)
Title
Number of participants with tunnel infection as an adverse event
Description
Number of participants with a tunnel infection for the duration of catheter use or to 180 days post device placement (whichever occurs first)
Time Frame
Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)
Title
Number of participants with exit site infection as an adverse event
Description
Number of participants with a exit site infection for the duration of catheter use or to 180 days post device placement (whichever occurs first)
Time Frame
Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)
Title
Number of participants with Pneumothorax, haemothorax, arrhythmia, air embolism or arterial perforation as an adverse event.
Description
Number of participants with non-infectious catheter complications within one day of placement.
Time Frame
1 day of device placement
Title
Number of participants with Catheter dislodgement, Catheter tip dislodgement and catheter thrombosis as an adverse event.
Description
Number of participants with late non infectious complications for the duration of catheter use or to 180 days post device placement (whichever occurs first).
Time Frame
Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: The patient shall be 18 - 80 years old. The patient requires the placement of a long term tunnelled HD catheter for administration of hemodialysis. The patient has anticipated survival in excess of 90 days from the anticipated date of catheter placement. The patient has the ability to understand the research subject information and sign a written Informed Consent form which must be obtained prior to initiation of the study. The patient receives the catheter via the internal jugular or subclavian vein. All female patients of child bearing potential must complete a negative pregnancy test and will confirm that they are not breastfeeding. Exclusion Criteria: The patient is participating in another IRB (Institutional Review Board) clinical trial, which modifies standard-of-care treatment and/or involves an investigational device or drug. The patient has a confirmed or suspected infection, bacteraemia or septicaemia. The patient's physiology is NOT suitable for placement of the NexSite device; this will include an examination of the anatomy at the proposed catheter exit site. The patient is known or suspected to have allergies to the materials used in the construction of the device. The patient has previously suffered from coagulation issues or has had vascular surgery at the proposed placement site. The patient has received radiation treatment at the proposed catheter placement site. The patient has severe chronic obstructive lung disease. The patient is pyretic within 72 hours (temperature ≥38o C or 100.4oF) prior to placement and/or has received antimicrobial drugs within two weeks prior to catheterisation. The patient is female of child bearing potential not using adequate contraception. (Adequate contraception is defined as abstinence, intrauterine device [IUD], birth control pills, or spermicidal gel with diaphragm or condom) The patient has another indwelling catheter. The patient has non-healing diabetic foot ulcers. The patient did not give informed consent. The patient would be unavailable for follow-up. The patient is a permanent nursing home resident. The proposed access site is not the internal jugular or subclavian vein. The patient is scheduled to undergo an elective surgical procedure (other than a procedure to create a graft or fistula) within the study timeframe. Any other condition that the Investigator believes should exclude the patient from the study. The patient does not have English or Spanish as their first language.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jeffrey G Hoggard, MD
Organizational Affiliation
Capital Nephrology Associates
Official's Role
Principal Investigator
Facility Information:
Facility Name
Eastern Nephrology Associates
City
Greenville
State/Province
North Carolina
ZIP/Postal Code
27834
Country
United States
Facility Name
Eastern Nephology Associates
City
New Bern
State/Province
North Carolina
ZIP/Postal Code
28542
Country
United States
Facility Name
Capital Nephrology Associates
City
Raleigh
State/Province
North Carolina
ZIP/Postal Code
27610
Country
United States
Facility Name
South Carolina Nephrology and Hypertension Center Inc
City
Orangeburg
State/Province
South Carolina
ZIP/Postal Code
29118
Country
United States
Facility Name
Lubbock Vascular Access Centre
City
Lubbock
State/Province
Texas
ZIP/Postal Code
79416
Country
United States
Facility Name
Renal Associates
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78215
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Analysis of CRBSI Rates in Patients With a NexSite™ HD (Hemodialysis) Catheter

We'll reach out to this number within 24 hrs